Cargando…
Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”
Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic and local, regional and national public health policies to limit coronavirus spread as well as “reopen” cities and states, are best informed by serum neutralizing antibody titers measured by reprodu...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081167/ https://www.ncbi.nlm.nih.gov/pubmed/33909646 http://dx.doi.org/10.1371/journal.pone.0250319 |
_version_ | 1783685583078424576 |
---|---|
author | Jin, Daniel K. Nesbitt, Daniel J. Yang, Jenny Chen, Haidee Horowitz, Julie Jones, Marcus Vandergaast, Rianna Carey, Timothy Reiter, Samantha Russell, Stephen J. Kyratsous, Christos Hooper, Andrea Hamilton, Jennifer Ferreira, Manuel Deng, Sarah Straus, Donna Baras, Aris Hillyer, Christopher D. Luchsinger, Larry L. |
author_facet | Jin, Daniel K. Nesbitt, Daniel J. Yang, Jenny Chen, Haidee Horowitz, Julie Jones, Marcus Vandergaast, Rianna Carey, Timothy Reiter, Samantha Russell, Stephen J. Kyratsous, Christos Hooper, Andrea Hamilton, Jennifer Ferreira, Manuel Deng, Sarah Straus, Donna Baras, Aris Hillyer, Christopher D. Luchsinger, Larry L. |
author_sort | Jin, Daniel K. |
collection | PubMed |
description | Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic and local, regional and national public health policies to limit coronavirus spread as well as “reopen” cities and states, are best informed by serum neutralizing antibody titers measured by reproducible, high throughput, and statically credible antibody (Ab) assays. To date, a myriad of Ab tests, both available and FDA authorized for emergency, has led to confusion rather than insight per se. The present study reports the results of a rapid, point-in-time 1,000-person cohort study using serial blood donors in the New York City metropolitan area (NYC) using multiple serological tests, including enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). These were then tested and associated with assays for neutralizing Ab (NAb). Of the 1,000 NYC blood donor samples in late June and early July 2020, 12.1% and 10.9% were seropositive using the Ortho Total Ig and the Abbott IgG HTSA assays, respectively. These serological assays correlated with neutralization activity specific to SARS-CoV-2. The data reported herein suggest that seroconversion in this population occurred in approximately 1 in 8 blood donors from the beginning of the pandemic in NYC (considered March 1, 2020). These findings deviate with an earlier seroprevalence study in NYC showing 13.7% positivity. Collectively however, these data demonstrate that a low number of individuals have serologic evidence of infection during this “first wave” and suggest that the notion of “herd immunity” at rates of ~60% or higher are not near. Furthermore, the data presented herein show that the nature of the Ab-based immunity is not invariably associated with the development of NAb. While the blood donor population may not mimic precisely the NYC population as a whole, rapid assessment of seroprevalence in this cohort and serial reassessment could aid public health decision making. |
format | Online Article Text |
id | pubmed-8081167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-80811672021-05-06 Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening” Jin, Daniel K. Nesbitt, Daniel J. Yang, Jenny Chen, Haidee Horowitz, Julie Jones, Marcus Vandergaast, Rianna Carey, Timothy Reiter, Samantha Russell, Stephen J. Kyratsous, Christos Hooper, Andrea Hamilton, Jennifer Ferreira, Manuel Deng, Sarah Straus, Donna Baras, Aris Hillyer, Christopher D. Luchsinger, Larry L. PLoS One Research Article Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic and local, regional and national public health policies to limit coronavirus spread as well as “reopen” cities and states, are best informed by serum neutralizing antibody titers measured by reproducible, high throughput, and statically credible antibody (Ab) assays. To date, a myriad of Ab tests, both available and FDA authorized for emergency, has led to confusion rather than insight per se. The present study reports the results of a rapid, point-in-time 1,000-person cohort study using serial blood donors in the New York City metropolitan area (NYC) using multiple serological tests, including enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). These were then tested and associated with assays for neutralizing Ab (NAb). Of the 1,000 NYC blood donor samples in late June and early July 2020, 12.1% and 10.9% were seropositive using the Ortho Total Ig and the Abbott IgG HTSA assays, respectively. These serological assays correlated with neutralization activity specific to SARS-CoV-2. The data reported herein suggest that seroconversion in this population occurred in approximately 1 in 8 blood donors from the beginning of the pandemic in NYC (considered March 1, 2020). These findings deviate with an earlier seroprevalence study in NYC showing 13.7% positivity. Collectively however, these data demonstrate that a low number of individuals have serologic evidence of infection during this “first wave” and suggest that the notion of “herd immunity” at rates of ~60% or higher are not near. Furthermore, the data presented herein show that the nature of the Ab-based immunity is not invariably associated with the development of NAb. While the blood donor population may not mimic precisely the NYC population as a whole, rapid assessment of seroprevalence in this cohort and serial reassessment could aid public health decision making. Public Library of Science 2021-04-28 /pmc/articles/PMC8081167/ /pubmed/33909646 http://dx.doi.org/10.1371/journal.pone.0250319 Text en © 2021 Jin et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Jin, Daniel K. Nesbitt, Daniel J. Yang, Jenny Chen, Haidee Horowitz, Julie Jones, Marcus Vandergaast, Rianna Carey, Timothy Reiter, Samantha Russell, Stephen J. Kyratsous, Christos Hooper, Andrea Hamilton, Jennifer Ferreira, Manuel Deng, Sarah Straus, Donna Baras, Aris Hillyer, Christopher D. Luchsinger, Larry L. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening” |
title | Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening” |
title_full | Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening” |
title_fullStr | Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening” |
title_full_unstemmed | Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening” |
title_short | Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening” |
title_sort | seroprevalence of anti-sars-cov-2 antibodies in a cohort of new york city metro blood donors using multiple sars-cov-2 serological assays: implications for controlling the epidemic and “reopening” |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081167/ https://www.ncbi.nlm.nih.gov/pubmed/33909646 http://dx.doi.org/10.1371/journal.pone.0250319 |
work_keys_str_mv | AT jindanielk seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT nesbittdanielj seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT yangjenny seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT chenhaidee seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT horowitzjulie seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT jonesmarcus seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT vandergaastrianna seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT careytimothy seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT reitersamantha seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT russellstephenj seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT kyratsouschristos seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT hooperandrea seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT hamiltonjennifer seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT ferreiramanuel seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT dengsarah seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT strausdonna seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT barasaris seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT hillyerchristopherd seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening AT luchsingerlarryl seroprevalenceofantisarscov2antibodiesinacohortofnewyorkcitymetroblooddonorsusingmultiplesarscov2serologicalassaysimplicationsforcontrollingtheepidemicandreopening |